Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant T-VEC in High Risk Early Melanoma
NCT04427306Phase 2Suspended
- Sponsor
- University of California, Davis
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of talimogene laherparepvec in melanoma, sponsored by University of California, Davis. Started May 2020; status: suspended.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04427306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04427306.